Johnson & Johnson Reports registry Data for Obinutuzumab in Sickle cell disease

Johnson & Johnson today announced registry results for obinutuzumab in patients with sickle cell disease. The study demonstrated that obinutuzumab demonstrates durable remissions compared to standard of care or placebo. These results provide important insights into the treatment of sickle cell disease and support the continued development of obinutuzumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.